1. Home
  2. INTU vs ARGX Comparison

INTU vs ARGX Comparison

Compare INTU & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intuit Inc.

INTU

Intuit Inc.

HOLD

Current Price

$325.40

Market Cap

79.6B

Sector

Technology

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$865.04

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTU
ARGX
Founded
1983
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.6B
58.4B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
INTU
ARGX
Price
$325.40
$865.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
20
19
Target Price
$692.35
$1,008.56
AVG Volume (30 Days)
3.7M
272.8K
Earning Date
05-21-2026
05-07-2026
Dividend Yield
1.22%
N/A
EPS Growth
31.06
N/A
EPS
15.05
N/A
Revenue
$18,831,000,000.00
N/A
Revenue This Year
$15.03
$44.39
Revenue Next Year
$12.41
$20.84
P/E Ratio
$21.39
$33.69
Revenue Growth
15.63
N/A
52 Week Low
$252.84
$631.74
52 Week High
$750.55
$953.58

Technical Indicators

Market Signals
Indicator
INTU
ARGX
Relative Strength Index (RSI) 59.69 50.64
Support Level $300.50 $822.56
Resistance Level $336.94 $881.89
Average True Range (ATR) 13.14 26.32
MACD 3.50 -2.43
Stochastic Oscillator 74.09 44.64

Price Performance

Historical Comparison
INTU
ARGX

About INTU Intuit Inc.

Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: